Literature DB >> 10499719

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.

A S Moore1, C A London, C A Wood, L E Williams, S M Cotter, D A L'Heureux, A E Frimberger.   

Abstract

Forty-three dogs with lymphoma that had relapsed or had failed to achieve complete remission to previous chemotherapy were treated with lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea [CCNU]) at a dosage of 90-100 mg/m2 body surface area p.o. every 3 weeks. Durable complete or partial responses occurred in 11 dogs for a median of 86 days. The acutely dose-limiting toxicosis was neutropenia 7 days after administration, resulting in a recommended dosage of 90 mg/m2. Cumulative thrombocytopenia occurred in dogs receiving continued CCNU treatment, and a dose interval of 3 weeks may be too short for continued administration of this drug. Toxicoses evident as fever or central nervous system signs or renal damage were uncommon or rare. CCNU is effective in the treatment of relapsed lymphoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499719     DOI: 10.1892/0891-6640(1999)013<0395:lfttor>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  8 in total

1.  Expression of O(6)-methylguanine-DNA methyltransferase causes lomustine resistance in canine lymphoma cells.

Authors:  Satoshi Kambayashi; Kouji Minami; Yuka Ogawa; Takehiro Hamaji; Chung Chew Hwang; Masaya Igase; Hiroko Hiraoka; Takako Shimokawa Miyama; Shunsuke Noguchi; Kenji Baba; Takuya Mizuno; Masaru Okuda
Journal:  Can J Vet Res       Date:  2015-07       Impact factor: 1.310

2.  The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.

Authors:  Melissa Parsons-Doherty; Valerie J Poirier; Gabrielle Monteith
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

3.  Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.

Authors:  Megan E Duffy; Christie L Anderson; Kevin Choy; Janean L Fidel
Journal:  Can Vet J       Date:  2018-02       Impact factor: 1.008

4.  Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.

Authors:  J H Burton; S D Stanley; H K Knych; C O Rodriguez; K A Skorupski; R B Rebhun
Journal:  J Vet Intern Med       Date:  2015-12-18       Impact factor: 3.333

5.  Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.

Authors:  Hiroki Yamazaki; Naoki Miura; Yu-Chang Lai; Masashi Takahashi; Yuko Goto-Koshino; Momoi Yasuyuki; Munekazu Nakaichi; Hajime Tsujimoto; Asuka Setoguchi; Yasuyuki Endo
Journal:  J Vet Med Sci       Date:  2017-06-06       Impact factor: 1.267

6.  Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.

Authors:  Heather L Gardner; Sarah B Rippy; Misty D Bear; Kim L Cronin; Heather Heeb; Holly Burr; Claire M Cannon; Kumar V Penmetsa; Srikant Viswanadha; Swaroop Vakkalanka; Cheryl A London
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

7.  Prediction of cancer drugs by chemical-chemical interactions.

Authors:  Jing Lu; Guohua Huang; Hai-Peng Li; Kai-Yan Feng; Lei Chen; Ming-Yue Zheng; Yu-Dong Cai
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

8.  Phase I dose-escalation study of nimustine in tumor-bearing dogs.

Authors:  Masashi Takahashi; Yuko Goto-Koshino; Kenjiro Fukushima; Hideyuki Kanemoto; Ko Nakashima; Yasuhito Fujino; Koichi Ohno; Yasuyuki Endo; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2014-02-10       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.